ClinicalTrials.gg
CompletedNCT05093205Updated Aug 19, 2024Results posted

STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS

A Phase 1 interventional study of PF-06882961 and Atorvastatin in Healthy Adults, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-19.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to characterize the effect of PF-06882961, administered at 2 steady-state dose levels, on the PK of single doses of atorvastatin (20 mg) or midazolam (5 mg), administered separately, in healthy adult male and female participants (Part A), or an OC in healthy PM female participants (Part B).

02

Conditions studied

  • Healthy Adults
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part A Only - Healthy male and female participants must be 18 to 65 years of age, inclusive, at the time of signing the ICD (healthy is defined as no abnormalities identified by a detailed medical history, physical examination, including blood pressure and pulse rate measurement, standard 12 lead and clinical laboratory tests).
  • Part B Only - Healthy PM female participants between 40 and 65 years of age, inclusive, at the time of signing the ICD (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, physical examination, including BP and PR measurement, standard 12 lead ECG and clinical laboratory tests). Subjects must be amenorrheic for at least 12 months. Women who are 60 years of age or younger must also have an FSH that is within the laboratory's reference range for PM women.
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • - 20.0 kg/m2 to \<30.0 kg/m2 at Screening.
  • Stable body weight, defined as \<5 % change (per participant report) for 90 days before Screening.
  • Capable of giving signed as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Any condition possibly affecting drug absorption (eg, prior bariatric surgery, gastrectomy, or any area of intestinal resection, active inflammatory bowel disease or pancreatic insufficiency).
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Known intolerance or to GLP-1R agonists.
  • Known hypersensitivity to atorvastatin or midazolam (for participants in Part A), or LE and EE (for participants in Part B).
  • Personal or family history of MTC or MEN2 or study participants with suspected MTC per the investigator's judgment.
  • Symptomatic gallbladder disease.
  • History of major depressive disorder or history of other severe psychiatric disorders (eg, schizophrenia or bipolar disorder) within the last 2 years from screening.
  • Any lifetime history of a suicide attempt.
  • Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study intervention.
  • Systemic therapy with any of the medications that are moderate or strong /5, CYP2C9 and/or CYP2C19 inhibitors within 28 days or 5 half-lives (whichever is longer) or moderate or strong CYP3A, CYP2C9 and/or CYP2C19 inducers within 28 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
  • Systemic therapy with inhibitors of the BCRP transporter within 28 days or 5 half lives (whichever is longer) prior to the first dose of study intervention.
  • Current use of any prohibited concomitant medication(s) or those unwilling/unable to use a permitted concomitant medication(s).
  • Previous administration with an drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer).
  • Known prior participation in a trial involving PF-06882961.
  • A PHQ-9 score ≥15 obtained at Screening or Day -1 in Study.
  • Response of "yes" to question 4 or 5, or on any suicidal behavioral question on the C SSRS at Screening or Day -1 in Study.
  • A positive urine drug test.
  • Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. BP should be measured in triplicate and the average of the 3 BP values should be used to determine the participant's eligibility. Note: At screening, the participant's arm circumference should be measured (eg, using a flexible anthropometric tape) at the midpoint of the length of the upper arm and the appropriate cuff selected and used throughout the study.
  • Screening 12-lead that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, interval >450 msec, complete LBBB, signs of an acute or indeterminate age myocardial infarction, ST-T interval changes suggestive of myocardial ischemia, second or third degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or QRS values should be used to determine the participant's eligibility. Computer interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants.
  • Participants with ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:

    • ≥6.5%.
    • Aspartate or ALT level ≥2 times the .
    • Total level ≥1.5 times the ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ ULN.
    • TSH >1.5x the ULN or \<LLN.
    • Serum calcitonin > the ULN.
    • Amylase or lipase > the ULN.
    • Fasting blood glucose ≥126 mg/dL.
    • Fasting C-peptide \<0.8 ng/mL.
    • \<70 mL/min/1.73 m2 as calculated by the CKD-EPI equation.
    • Positive testing for , HepBsAg, or HCVAb. Study participants positive for HCVAb are to be excluded unless known to have been treated with a known curative therapy and negative for . vaccination is allowed.
    • A positive SARS-CoV-2 test.
  • Participation in a formal weight reduction program (eg, Weight Watchers) within 90 days prior to Screening.
  • History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).
  • Current use of tobacco or nicotine containing products in excess of the equivalent of 5 cigarettes per day.
  • Known or suspected illicit drug use.
  • Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing randomization (Day-1).
  • History of sensitivity to heparin or heparin induced thrombocytopenia if Hep-lock is used for IV blood draw.
  • Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.
  • Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Part A

    To evaluate the effect of 2 steady-state dose levels of PF-06882961 on the Single Dose pharmacokinetics of atorvastatin (20 mg tablet) and midazolam (5 mg syrup).

    Drug: PF-06882961 · Drug: Atorvastatin · Drug: Midazolam

  • Experimental
    Part B

    To evaluate the effect of 2 steady-state dose levels of PF-06882961 on the Single Dose pharmacokinetics of an Oral Contraceptive (Levonorgestrel 0.15 mg and Ethinyl Estradiol 0.03 mg tablet).

    Drug: PF-06882961 · Drug: Levonorgestrel & Ethinyl Estradiol

Interventions

06

What researchers measure

Primary outcomes

  1. (Part A) Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of Atorvastatin in Periods 1, 4, and 7

    Atorvastatin was given on Day 1 in Periods 1, 4 and 7 of Part A and blood samples were collected for atorvastatin pharmacokinetic (PK) at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

    Time frame: For Part A Periods 1, 4, and 7: At 0 (prior to atorvastatin dose), 0.5, 1, 1.5, 2, 4, 6, 9, 12, 24, 36, 48, 72 hours (only Periods 1 & 4) post atorvastatin dose on Day 1 of each period.

  2. (Part A) AUCinf of Midazolam in Periods 2, 5, and 8

    Midazolam was given on Day 1 in Periods 2, 5 and 8 of Part A and blood samples were collected for midazolam PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

    Time frame: For Part A Periods 2, 5, and 8: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours (only for Periods 2 & 5) post midazolam dose on Day 1 of each period.

  3. (Part B) AUCinf of Levonorgestrel in Periods 1, 3 and 5

    Levonorgestrel was given on Day 1 in Periods 1, 3 and 5 of Part B and blood samples were collected for levonorgestrel PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

    Time frame: For Part B Periods 1, 3, 5: At 0 (prior to levonorgestrel dose), 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48, 72, 96, 120 hours post levonorgestrel dose on Day 1 of each period.

  4. (Part B) AUCinf of Ethinyl Estradiol in Periods 1, 3 and 5

    Ethinyl estradiol (EE) was given on Day 1 in Periods 1, 3 and 5 of Part B and blood samples were collected for ethinyl estradiol PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

    Time frame: For Part B Periods 1, 3, 5: At 0 (prior to EE dose), 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48, 72, 96, 120 hours post EE dose on Day 1 in Periods 1, 3, 5 of each period.

Secondary outcomes

  1. (Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study

    An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event was defined as any untoward medical occurrence that,at any dose:resulted in death;was life-threatening;required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent disability/incapacity; was a congenital anomaly/birth defect;or other serious situations such as important medical events. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.

    Time frame: From Baseline up to follow-up telephone contact (Days 90-97) in Part A of the study.

  2. (Part B) Number of Participants With TEAE During Part B of the Study

    An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event was defined as any untoward medical occurrence that,at any dose:resulted in death;was life-threatening;required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent disability/incapacity; was a congenital anomaly/birth defect;or other serious situations such as important medical events. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.

    Time frame: From Baseline up to follow-up telephone contact (Days 94-101) in Part B of the study.

  3. (Part A) Number of Participants With Clinical Laboratory Abnormalities During Part A of the Study (Without Regard to Baseline Abnormality)

    Laboratory tests (including hematology, clinical chemistry, urinalysis) were reported and abnormalities were defined for laboratory values that met specific criteria.

    Time frame: From Baseline up to follow-up visit (Days 69-72) in Part A of the study.

  4. (Part B) Number of Participants With Clinical Laboratory Abnormalities During Part B of the Study (Without Regard to Baseline Abnormality)

    Laboratory tests (including hematology, clinical chemistry, urinalysis) were reported and abnormalities were defined for laboratory values that met specific criteria.

    Time frame: From Baseline up to follow-up visit (Days 72-75) in Part B of the study.

  5. (Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study

    Supine blood pressure (mm Hg) and pulse rate (beats per minute) were measured. Supine BP was measured with the participant's arm supported at heart level and recorded to the nearest mmHg after approximately 5 minutes of rest.

    Time frame: From Baseline up to follow-up visit (Days 69-72) in Part A of the study.

  6. (Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study

    Supine blood pressure (mm Hg) and pulse rate (bpm) were measured. Supine BP was measured with the participant's arm supported at heart level and recorded to the nearest mmHg after approximately 5 minutes of rest.

    Time frame: From Baseline up to follow-up visit (Days 72-75) in Part B of the study.

  7. (Part A) Percentage of Change From Baseline in Body Weight

    Percentage of changes from Baseline in body weight of the participants were measured.

    Time frame: Percentage of change from Baseline 1: from the last pre-dose measurement in Part A Period 1 (ie, Baseline 1) to Day 2 of Part A Period 8; percentage of Change from the last predose measurement in Part A Period 3 (ie, Baseline 2) to Day 2 of Period 8.

  8. (Part B) Percentage of Change From Baseline in Body Weight

    Percentage of changes from Baseline in body weight of the participants were measured.

    Time frame: Percentage of Change from Baseline 1:from the last pre-dose measurement in Part B Period 1 (ie, Baseline 1) to Day 2 of Part B Period 8;percentage of Change from the last predose measurement in Part B Period 2 (ie, Baseline 2) to Day 6 of Part B Period 5.

  9. (Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study

    Standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measured PR, QT, and QT interval corrected for heart rate (QTc) and QRS complex.

    Time frame: From Baseline up to follow-up visit (Days 69-72) in Part A of the study.

  10. (Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study

    Standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measured PR, QT, and QT interval corrected for heart rate (QTc) and QRS complex.

    Time frame: From Baseline up to follow-up visit (Days 72-75) in Part B of the study.

  11. (Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").

    Time frame: Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D5 (P3D1), D12 (P3D8), D19 (P3D15), D27 (P3D23), D36 (P4D1), D40 (P6D1), D48 (P6D9), D58 (P6D19), D62 (P8D1), and at follow-up visit (Days 69-72) of Part A.

  12. (Part B) Number of Participants With Categorical Scores on the C-SSRS

    The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").

    Time frame: Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D6 (P2D1), D13 (P2D8), D20 (P2D15), D27 (P2D22), D37 (P3D1), D42 (P4D1), D50 (P4D9), D60 (P4D19), D66 (P5D6), and at follow-up visit (Days 72-75) of Part B.

  13. (Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9)

    The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included "little interest/pleasure in things", "feeling down depressed or hopeless", "trouble falling or staying asleep", "feeling tired or little energy", "poor appetite or overeating", "feeling bad about yourself", "trouble concentrating on things", "moving slowly or fidgety/restless" and "thoughts you be better off dead". Each item was scored on scale of "not at all", "several days", "more than half the days" to "nearly every day". Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity).

    Time frame: Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D5 (P3D1), D12 (P3D8), D19 (P3D15), D27 (P3D23), D36 (P4D1), D40 (P6D1), D48 (P6D9), D58 (P6D19), D62 (P8D1), and at follow-up visit (Days 69-72) of Part A.

  14. (Part B) Number of Participants With Categorical Scores on the PHQ-9

    The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included "little interest/pleasure in things", "feeling down depressed or hopeless", "trouble falling or staying asleep", "feeling tired or little energy", "poor appetite or overeating", "feeling bad about yourself", "trouble concentrating on things", "moving slowly or fidgety/restless" and "thoughts you be better off dead". Each item was scored on scale of "not at all", "several days", "more than half the days" to "nearly every day". Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity).

    Time frame: Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D6 (P2D1), D13 (P2D8), D20 (P2D15), D27 (P2D22), D37 (P3D1), D42 (P4D1), D50 (P4D9), D60 (P4D19), D66 (P5D6), and at follow-up visit (Days 72-75) of Part B.

07

Results

Posted Aug 19, 2024
Limitations and caveats
In part A, a majority of participants discontinued from study interventions due to SARS-CoV-2 infection and data from only 3 to 4 participants were evaluable following administration of danuglipron 200 mg BID. The resulting data should, therefore, be interpreted with caution.

Participant flow

Part A Period 1 - Treatment
Participant flow — Part A Period 1 - Treatment
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started18000000000000
Completed18000000000000
Not completed0000000000000
Part A Period 1 - Follow-Up
Participant flow — Part A Period 1 - Follow-Up
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started15000000000000
Completed15000000000000
Not completed0000000000000
Part A Period 2 - Treatment
Participant flow — Part A Period 2 - Treatment
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started01800000000000
Completed01700000000000
Not completed0100000000000
Withdrew: Physician decision0100000000000
Part A Period 2 - Follow-Up
Participant flow — Part A Period 2 - Follow-Up
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started01500000000000
Completed01500000000000
Not completed0000000000000
Part A Period 3 - Treatment
Participant flow — Part A Period 3 - Treatment
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started00170000000000
Completed00130000000000
Not completed0040000000000
Withdrew: Withdrawal by subject0010000000000
Withdrew: Physician decision0010000000000
Withdrew: Adverse event0020000000000
Part A Period 3 - Follow-Up
Participant flow — Part A Period 3 - Follow-Up
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started00150000000000
Completed00150000000000
Not completed0000000000000
Part A Period 4 - Treatment
Participant flow — Part A Period 4 - Treatment
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started00013000000000
Completed00013000000000
Not completed0000000000000
Part A Period 4 - Follow-Up
Participant flow — Part A Period 4 - Follow-Up
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started00013000000000
Completed00013000000000
Not completed0000000000000
Part A Period 5 - Treatment
Participant flow — Part A Period 5 - Treatment
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started00001300000000
Completed00001300000000
Not completed0000000000000
Part A Period 5 - Follow-Up
Participant flow — Part A Period 5 - Follow-Up
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started00001300000000
Completed00001300000000
Not completed0000000000000
Part A Period 6 - Treatment
Participant flow — Part A Period 6 - Treatment
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started00000130000000
Completed0000060000000
Not completed0000070000000
Withdrew: Adverse event0000070000000
Part A Period 6 - Follow-Up
Participant flow — Part A Period 6 - Follow-Up
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started00000130000000
Completed00000130000000
Not completed0000000000000
Part A Period 7 - Treatment
Participant flow — Part A Period 7 - Treatment
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started0000005000000
Completed0000005000000
Not completed0000000000000
Part A Period 7 - Follow-Up
Participant flow — Part A Period 7 - Follow-Up
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started0000005000000
Completed0000005000000
Not completed0000000000000
Part A Period 8 - Treatment
Participant flow — Part A Period 8 - Treatment
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started0000000600000
Completed0000000500000
Not completed0000000100000
Withdrew: Adverse event0000000100000
Part A Period 8 - Follow-Up
Participant flow — Part A Period 8 - Follow-Up
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started0000000600000
Completed0000000600000
Not completed0000000000000
Part B Period 1 - Treatment
Participant flow — Part B Period 1 - Treatment
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started00000000170000
Completed00000000160000
Not completed0000000010000
Withdrew: Protocol violation0000000010000
Part B Period 1 - Follow-Up
Participant flow — Part B Period 1 - Follow-Up
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started00000000150000
Completed00000000150000
Not completed0000000000000
Part B Period 2 - Treatment
Participant flow — Part B Period 2 - Treatment
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started00000000016000
Completed00000000014000
Not completed0000000002000
Withdrew: Adverse event0000000002000
Part B Period 2 - Follow-Up
Participant flow — Part B Period 2 - Follow-Up
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started00000000015000
Completed00000000014000
Not completed0000000001000
Withdrew: Withdrawal by subject0000000001000
Part B Period 3 - Treatment
Participant flow — Part B Period 3 - Treatment
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started00000000001400
Completed00000000001200
Not completed0000000000200
Withdrew: Adverse event0000000000200
Part B Period 3 - Follow-Up
Participant flow — Part B Period 3 - Follow-Up
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started00000000001300
Completed00000000001100
Not completed0000000000200
Withdrew: Withdrawal by subject0000000000200
Part B Period 4 - Treatment
Participant flow — Part B Period 4 - Treatment
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started00000000000120
Completed0000000000090
Not completed0000000000030
Withdrew: Withdrawal by subject0000000000010
Withdrew: Adverse event0000000000020
Part B Period 4 - Follow-Up
Participant flow — Part B Period 4 - Follow-Up
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started00000000000110
Completed00000000000100
Not completed0000000000010
Withdrew: Withdrawal by subject0000000000010
Part B Period 5 - Treatment
Participant flow — Part B Period 5 - Treatment
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started0000000000009
Completed0000000000009
Not completed0000000000000
Part B Period 5 - Follow-Up
Participant flow — Part B Period 5 - Follow-Up
MilestoneAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Started0000000000009
Completed0000000000009
Not completed0000000000000

Outcome measures

Primary(Part A) Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of Atorvastatin in Periods 1, 4, and 7

Atorvastatin was given on Day 1 in Periods 1, 4 and 7 of Part A and blood samples were collected for atorvastatin pharmacokinetic (PK) at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

Time frame:
For Part A Periods 1, 4, and 7: At 0 (prior to atorvastatin dose), 0.5, 1, 1.5, 2, 4, 6, 9, 12, 24, 36, 48, 72 hours (only Periods 1 & 4) post atorvastatin dose on Day 1 of each period.
Reported as:
Geometric mean · nanogram*hour/milliliter (ng*hr/mL)
(Part A) Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of Atorvastatin in Periods 1, 4, and 7
nanogram*hour/milliliter (ng*hr/mL)Atorvastatin 20 mg (Part A Period 1)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)
(Part A) Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of Atorvastatin in Periods 1, 4, and 732.27 ± 4146.94 ± 7254.43 ± 22
Primary(Part A) AUCinf of Midazolam in Periods 2, 5, and 8

Midazolam was given on Day 1 in Periods 2, 5 and 8 of Part A and blood samples were collected for midazolam PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

Time frame:
For Part A Periods 2, 5, and 8: At 0 (prior to midazolam dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours (only for Periods 2 & 5) post midazolam dose on Day 1 of each period.
Reported as:
Geometric mean · ng*hr/mL
(Part A) AUCinf of Midazolam in Periods 2, 5, and 8
ng*hr/mLMidazolam 5 mg (Part A Period 2)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)
(Part A) AUCinf of Midazolam in Periods 2, 5, and 870.53 ± 3258.81 ± 4049.78 ± 22
Primary(Part B) AUCinf of Levonorgestrel in Periods 1, 3 and 5

Levonorgestrel was given on Day 1 in Periods 1, 3 and 5 of Part B and blood samples were collected for levonorgestrel PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

Time frame:
For Part B Periods 1, 3, 5: At 0 (prior to levonorgestrel dose), 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48, 72, 96, 120 hours post levonorgestrel dose on Day 1 of each period.
Reported as:
Geometric mean · picogram*hour/milliliter (pg*hr/mL)
(Part B) AUCinf of Levonorgestrel in Periods 1, 3 and 5
picogram*hour/milliliter (pg*hr/mL)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
(Part B) AUCinf of Levonorgestrel in Periods 1, 3 and 548800 ± 4262330 ± 6166490 ± 57
Statistical analysis
  • 0.15 mg LE & 0.03 mg EE (Part B Period 1) vs PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) · Mixed Models Analysis · Specified in comments: 122.48 · 90% CI 106.96 to 140.25A mixed effects model with treatment as a fixed effect and participant as a random effect was used was applied to calculate the ratio (Test/Reference) of adjusted means and 90% CIs for Ratio. The ratio (and 90% CI) is expressed as percentage.
  • 0.15 mg LE & 0.03 mg EE (Part B Period 1) vs PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) · Mixed Models Analysis · Specified in comments: 143.83 · 90% CI 122.64 to 168.68A mixed effects model with treatment as a fixed effect and participant as a random effect was used was applied to calculate the ratio (Test/Reference) of adjusted means and 90% CIs for Ratio. The ratio (and 90% CI) is expressed as percentage.
Primary(Part B) AUCinf of Ethinyl Estradiol in Periods 1, 3 and 5

Ethinyl estradiol (EE) was given on Day 1 in Periods 1, 3 and 5 of Part B and blood samples were collected for ethinyl estradiol PK at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.

Time frame:
For Part B Periods 1, 3, 5: At 0 (prior to EE dose), 0.5, 1, 1.5, 2, 4, 8, 12, 24, 48, 72, 96, 120 hours post EE dose on Day 1 in Periods 1, 3, 5 of each period.
Reported as:
Geometric mean · pg*hr/mL
(Part B) AUCinf of Ethinyl Estradiol in Periods 1, 3 and 5
pg*hr/mL0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
(Part B) AUCinf of Ethinyl Estradiol in Periods 1, 3 and 5772.1 ± 41723.5 ± 24604.4 ± 33
Statistical analysis
  • 0.15 mg LE & 0.03 mg EE (Part B Period 1) vs PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3) · Mixed Models Analysis · Specified in comments: 104.46 · 90% CI 92.56 to 117.89A mixed effects model with treatment as a fixed effect and participant as a random effect was used was applied to calculate the ratio (Test/Reference) of adjusted means and 90% CIs for Ratio. The ratio (and 90% CI) is expressed as percentage.
  • 0.15 mg LE & 0.03 mg EE (Part B Period 1) vs PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5) · Mixed Models Analysis · Specified in comments: 92.77 · 90% CI 81.05 to 106.19A mixed effects model with treatment as a fixed effect and participant as a random effect was used was applied to calculate the ratio (Test/Reference) of adjusted means and 90% CIs for Ratio. The ratio (and 90% CI) is expressed as percentage.
Secondary(Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study

An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event was defined as any untoward medical occurrence that,at any dose:resulted in death;was life-threatening;required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent disability/incapacity; was a congenital anomaly/birth defect;or other serious situations such as important medical events. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.

Time frame:
From Baseline up to follow-up telephone contact (Days 90-97) in Part A of the study.
Reported as:
Count of participants · Participants
(Part A) Number of Participants With Treatment Emergent Adverse Events (TEAE) During Part A of the Study
ParticipantsAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)
Participants with adverse events2313541252
Participants with serious adverse events00000000
Participants with severe adverse events00000000
Participants discontinued from study due to AEs00000000
Participants discontinued study drug due to AE and continue study00200701
Participants with dose reduced or temporary discontinuation due to AE00100400
Secondary(Part B) Number of Participants With TEAE During Part B of the Study

An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event was defined as any untoward medical occurrence that,at any dose:resulted in death;was life-threatening;required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent disability/incapacity; was a congenital anomaly/birth defect;or other serious situations such as important medical events. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.

Time frame:
From Baseline up to follow-up telephone contact (Days 94-101) in Part B of the study.
Reported as:
Count of participants · Participants
(Part B) Number of Participants With TEAE During Part B of the Study
Participants0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Participants with adverse events5157127
Participants with serious adverse events00000
Participants with severe adverse events00000
Participants discontinued from study due to AEs00000
Participants discontinued study drug due to AE and continue study02220
Participants with dose reduced or temporary discontinuation due to AE02020
Secondary(Part A) Number of Participants With Clinical Laboratory Abnormalities During Part A of the Study (Without Regard to Baseline Abnormality)

Laboratory tests (including hematology, clinical chemistry, urinalysis) were reported and abnormalities were defined for laboratory values that met specific criteria.

Time frame:
From Baseline up to follow-up visit (Days 69-72) in Part A of the study.
Reported as:
Count of participants · Participants
(Part A) Number of Participants With Clinical Laboratory Abnormalities During Part A of the Study (Without Regard to Baseline Abnormality)
ParticipantsAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)
(Part A) Number of Participants With Clinical Laboratory Abnormalities During Part A of the Study (Without Regard to Baseline Abnormality)01516251206
Secondary(Part B) Number of Participants With Clinical Laboratory Abnormalities During Part B of the Study (Without Regard to Baseline Abnormality)

Laboratory tests (including hematology, clinical chemistry, urinalysis) were reported and abnormalities were defined for laboratory values that met specific criteria.

Time frame:
From Baseline up to follow-up visit (Days 72-75) in Part B of the study.
Reported as:
Count of participants · Participants
(Part B) Number of Participants With Clinical Laboratory Abnormalities During Part B of the Study (Without Regard to Baseline Abnormality)
Participants0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
(Part B) Number of Participants With Clinical Laboratory Abnormalities During Part B of the Study (Without Regard to Baseline Abnormality)17162129
Secondary(Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study

Supine blood pressure (mm Hg) and pulse rate (beats per minute) were measured. Supine BP was measured with the participant's arm supported at heart level and recorded to the nearest mmHg after approximately 5 minutes of rest.

Time frame:
From Baseline up to follow-up visit (Days 69-72) in Part A of the study.
Reported as:
Count of participants · Participants
(Part A) Number of Participants With Vital Signs Abnormalities During Part A of the Study
ParticipantsAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)
Supine systolic blood pressure (SBP) value <90 mm Hg00000000
Supine SBP change >=30 mm Hg increase00000000
Supine SBP change >=30 mm Hg decrease00121111
Supine diastolic blood pressure (DBP) value <50 mm Hg00000000
Supine DBP >= 20 mm Hg increase00000001
Supine DBP >= 20 mm Hg decrease11223121
Pulse rate value <40 bpm00000000
Pulse rate value >120 bpm00000000
Secondary(Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study

Supine blood pressure (mm Hg) and pulse rate (bpm) were measured. Supine BP was measured with the participant's arm supported at heart level and recorded to the nearest mmHg after approximately 5 minutes of rest.

Time frame:
From Baseline up to follow-up visit (Days 72-75) in Part B of the study.
Reported as:
Count of participants · Participants
(Part B) Number of Participants With Vital Signs Abnormalities During Part B of the Study
Participants0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
Supine SBP value <90 mm Hg00000
Supine SBP change >=30 mm Hg increase00000
Supine SBP change >=30 mm Hg decrease11011
Supine DBP value <50 mm Hg00000
Supine DBP >= 20 mm Hg increase00000
Supine DBP >= 20 mm Hg decrease13011
Pulse rate value <40 bpm00000
Pulse rate value >120 bpm00000
Secondary(Part A) Percentage of Change From Baseline in Body Weight

Percentage of changes from Baseline in body weight of the participants were measured.

Time frame:
Percentage of change from Baseline 1: from the last pre-dose measurement in Part A Period 1 (ie, Baseline 1) to Day 2 of Part A Period 8; percentage of Change from the last predose measurement in Part A Period 3 (ie, Baseline 2) to Day 2 of Period 8.
Reported as:
Mean · percentage
(Part A) Percentage of Change From Baseline in Body Weight
percentageAll Participants in Part A
Baseline 1 - Period 8 Day 2 / PF-06882961 200 mg BID + Midazolam 5 mg-9.04 ± 3.539
Baseline 2 - Period 8 Day 2 / PF-06882961 200 mg BID + Midazolam 5 mg-9.30 ± 4.159
Secondary(Part B) Percentage of Change From Baseline in Body Weight

Percentage of changes from Baseline in body weight of the participants were measured.

Time frame:
Percentage of Change from Baseline 1:from the last pre-dose measurement in Part B Period 1 (ie, Baseline 1) to Day 2 of Part B Period 8;percentage of Change from the last predose measurement in Part B Period 2 (ie, Baseline 2) to Day 6 of Part B Period 5.
Reported as:
Mean · percentage
(Part B) Percentage of Change From Baseline in Body Weight
percentageAll Participants in Part B
Baseline 1 - Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE-8.77 ± 2.190
Baseline 2 - Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE-5.40 ± 1.503
Secondary(Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study

Standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measured PR, QT, and QT interval corrected for heart rate (QTc) and QRS complex.

Time frame:
From Baseline up to follow-up visit (Days 69-72) in Part A of the study.
Reported as:
Count of participants · Participants
(Part A) Number of Participants With Treatment Emergent Electrocardiograms (ECG) Abnormalities During Part A of the Study
ParticipantsAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)
PR interval value >=300 msec00000000
PR interval %change >=25/50% msec00000000
QRS interval value >= 140 msec00000000
QRS interval %change >=50% msec00000000
QTcF 450 msec < value <=480 msec00000000
QTcF 480 msec < value <=500 msec00000000
QTcF value >500 msec00000000
QTcF 30 msec < change <=60 msec00120101
QTcF change >60 msec00000000
Secondary(Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study

Standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measured PR, QT, and QT interval corrected for heart rate (QTc) and QRS complex.

Time frame:
From Baseline up to follow-up visit (Days 72-75) in Part B of the study.
Reported as:
Count of participants · Participants
(Part B) Number of Participants With Treatment Emergent ECG Abnormalities During Part B of the Study
Participants0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
PR interval value >=300 msec00000
PR interval %change >=25/50% msec00000
QRS interval value >= 140 msec00000
QRS interval %change >=50% msec00000
QTcF 450 msec < value <=480 msec00010
QTcF 480 msec < value <=500 msec00000
QTcF value >500 msec00000
QTcF 30 msec < change <=60 msec00000
QTcF change >60 msec00000
Secondary(Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)

The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").

Time frame:
Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D5 (P3D1), D12 (P3D8), D19 (P3D15), D27 (P3D23), D36 (P4D1), D40 (P6D1), D48 (P6D9), D58 (P6D19), D62 (P8D1), and at follow-up visit (Days 69-72) of Part A.
Reported as:
Count of participants · Participants
(Part A) Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsAll Participants in Part A
Period 1 Day -1 / Atorvastatin 20 mg0
Period 1 Day -1 / Atorvastatin 20 mg Past 12 Months0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID (Since Last Visit)0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID (Since Last Visit)0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID (Since Last Visit)0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID (Since Last Visit)0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg (Since Last Visit)0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID (Since Last Visit)0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID (Since Last Visit)0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID (Since Last Visit)0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg (Since Last Visit)0
Follow Up (Since Last Visit)0
Secondary(Part B) Number of Participants With Categorical Scores on the C-SSRS

The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").

Time frame:
Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D6 (P2D1), D13 (P2D8), D20 (P2D15), D27 (P2D22), D37 (P3D1), D42 (P4D1), D50 (P4D9), D60 (P4D19), D66 (P5D6), and at follow-up visit (Days 72-75) of Part B.
Reported as:
Count of participants · Participants
(Part B) Number of Participants With Categorical Scores on the C-SSRS
ParticipantsAll Participants in Part B
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE (Past 12 months)0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID (Since Last Visit)0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID (Since Last Visit)0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID (Since Last Visit)0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID (Since Last Visit)0
Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Since Last Visit)0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID (Since Last Visit)0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID (Since Last Visit)0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID (Since Last Visit)0
Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Since Last Visit)0
Follow Up (Since Last Visit)0
Secondary(Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9)

The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included "little interest/pleasure in things", "feeling down depressed or hopeless", "trouble falling or staying asleep", "feeling tired or little energy", "poor appetite or overeating", "feeling bad about yourself", "trouble concentrating on things", "moving slowly or fidgety/restless" and "thoughts you be better off dead". Each item was scored on scale of "not at all", "several days", "more than half the days" to "nearly every day". Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity).

Time frame:
Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D5 (P3D1), D12 (P3D8), D19 (P3D15), D27 (P3D23), D36 (P4D1), D40 (P6D1), D48 (P6D9), D58 (P6D19), D62 (P8D1), and at follow-up visit (Days 69-72) of Part A.
Reported as:
Count of participants · Participants
(Part A) Number of Participants With Categorical Scores on the Patient Health Questionnaire (PHQ-9)
ParticipantsAll Participants in Part A
Period 1 Day -1 / Atorvastatin 20 mg / Little Interest/Pleasure in Things — Not At All18
Period 1 Day -1 / Atorvastatin 20 mg / Little Interest/Pleasure in Things — Several Days0
Period 1 Day -1 / Atorvastatin 20 mg / Little Interest/Pleasure in Things — More Than Half The Days0
Period 1 Day -1 / Atorvastatin 20 mg / Little Interest/Pleasure in Things — Nearly Every Day0
Period 1 Day -1 / Atorvastatin 20 mg / Feeling Down Depressed or Hopeless — Not At All18
Period 1 Day -1 / Atorvastatin 20 mg / Feeling Down Depressed or Hopeless — Several Days0
Period 1 Day -1 / Atorvastatin 20 mg / Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 1 Day -1 / Atorvastatin 20 mg / Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 1 Day -1 / Atorvastatin 20 mg / Trouble Falling or Staying Asleep — Not At All18
Period 1 Day -1 / Atorvastatin 20 mg / Trouble Falling or Staying Asleep — Several Days0
Period 1 Day -1 / Atorvastatin 20 mg / Trouble Falling or Staying Asleep — More Than Half The Days0
Period 1 Day -1 / Atorvastatin 20 mg / Trouble Falling or Staying Asleep — Nearly Every Day0
Period 1 Day -1 / Atorvastatin 20 mg / Feeling Tired or Little Energy — Not At All18
Period 1 Day -1 / Atorvastatin 20 mg / Feeling Tired or Little Energy — Several Days0
Period 1 Day -1 / Atorvastatin 20 mg / Feeling Tired or Little Energy — More Than Half The Days0
Period 1 Day -1 / Atorvastatin 20 mg / Feeling Tired or Little Energy — Nearly Every Day0
Period 1 Day -1 / Atorvastatin 20 mg / Poor Appetite or Overeating — Not At All18
Period 1 Day -1 / Atorvastatin 20 mg / Poor Appetite or Overeating — Several Days0
Period 1 Day -1 / Atorvastatin 20 mg / Poor Appetite or Overeating — More Than Half The Days0
Period 1 Day -1 / Atorvastatin 20 mg / Poor Appetite or Overeating — Nearly Every Day0
Period 1 Day -1 / Atorvastatin 20 mg / Feeling Bad About Yourself — Not At All18
Period 1 Day -1 / Atorvastatin 20 mg / Feeling Bad About Yourself — Several Days0
Period 1 Day -1 / Atorvastatin 20 mg / Feeling Bad About Yourself — More Than Half The Days0
Period 1 Day -1 / Atorvastatin 20 mg / Feeling Bad About Yourself — Nearly Every Day0
Period 1 Day -1 / Atorvastatin 20 mg / Trouble Concentrating on Things — Not At All18
Period 1 Day -1 / Atorvastatin 20 mg / Trouble Concentrating on Things — Several Days0
Period 1 Day -1 / Atorvastatin 20 mg / Trouble Concentrating on Things — More Than Half The Days0
Period 1 Day -1 / Atorvastatin 20 mg / Trouble Concentrating on Things — Nearly Every Day0
Period 1 Day -1 / Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless — Not At All18
Period 1 Day -1 / Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless — Several Days0
Period 1 Day -1 / Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 1 Day -1 / Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 1 Day -1 / Atorvastatin 20 mg / Thoughts You Be Better Off Dead — Not At All18
Period 1 Day -1 / Atorvastatin 20 mg / Thoughts You Be Better Off Dead — Several Days0
Period 1 Day -1 / Atorvastatin 20 mg / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 1 Day -1 / Atorvastatin 20 mg / Thoughts You Be Better Off Dead — Nearly Every Day0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Not At All17
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Several Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — More Than Half The Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Nearly Every Day0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Not At All17
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Several Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Not At All17
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Several Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Not At All17
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Several Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — More Than Half The Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Nearly Every Day0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Not At All17
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Several Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — More Than Half The Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Nearly Every Day0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Not At All17
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Several Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — More Than Half The Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Nearly Every Day0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Not At All17
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Several Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — More Than Half The Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Nearly Every Day0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Not At All17
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Several Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Not At All17
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Several Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 3 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Not At All16
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Several Days0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — More Than Half The Days0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Nearly Every Day0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Not At All16
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Several Days0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Not At All16
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Several Days0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Not At All16
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Several Days0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — More Than Half The Days0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Nearly Every Day0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Not At All15
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Several Days1
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — More Than Half The Days0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Nearly Every Day0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Not At All16
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Several Days0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — More Than Half The Days0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Nearly Every Day0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Not At All16
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Several Days0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — More Than Half The Days0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Nearly Every Day0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Not At All16
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Several Days0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Not At All16
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Several Days0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 3 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Not At All16
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Several Days0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — More Than Half The Days0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Nearly Every Day0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Not At All16
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Several Days0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Not At All16
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Several Days0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Not At All16
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Several Days0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — More Than Half The Days0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Nearly Every Day0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Not At All15
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Several Days1
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — More Than Half The Days0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Nearly Every Day0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Not At All16
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Several Days0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — More Than Half The Days0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Nearly Every Day0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Not At All16
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Several Days0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — More Than Half The Days0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Nearly Every Day0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Not At All16
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Several Days0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Not At All16
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Several Days0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 3 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Not At All15
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Several Days0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — More Than Half The Days0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Nearly Every Day0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Not At All15
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Several Days0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Not At All15
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Several Days0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Not At All15
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Several Days0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — More Than Half The Days0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Nearly Every Day0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Not At All12
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Several Days1
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — More Than Half The Days1
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Nearly Every Day1
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Not At All15
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Several Days0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — More Than Half The Days0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Nearly Every Day0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Not At All15
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Several Days0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — More Than Half The Days0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Nearly Every Day0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Not At All15
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Several Days0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Not At All15
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Several Days0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 3 Day 23 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Little Interest/Pleasure in Things — Not At All13
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Little Interest/Pleasure in Things — Several Days0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Little Interest/Pleasure in Things — More Than Half The Days0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Little Interest/Pleasure in Things — Nearly Every Day0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Down Depressed or Hopeless — Not At All13
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Down Depressed or Hopeless — Several Days0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Falling or Staying Asleep — Not At All13
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Falling or Staying Asleep — Several Days0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Falling or Staying Asleep — More Than Half The Days0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Falling or Staying Asleep — Nearly Every Day0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Tired or Little Energy — Not At All13
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Tired or Little Energy — Several Days0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Tired or Little Energy — More Than Half The Days0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Tired or Little Energy — Nearly Every Day0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Poor Appetite or Overeating — Not At All10
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Poor Appetite or Overeating — Several Days2
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Poor Appetite or Overeating — More Than Half The Days0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Poor Appetite or Overeating — Nearly Every Day1
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Bad About Yourself — Not At All13
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Bad About Yourself — Several Days0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Bad About Yourself — More Than Half The Days0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Feeling Bad About Yourself — Nearly Every Day0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Concentrating on Things — Not At All13
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Concentrating on Things — Several Days0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Concentrating on Things — More Than Half The Days0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Trouble Concentrating on Things — Nearly Every Day0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless — Not At All13
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless — Several Days0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Thoughts You Be Better Off Dead — Not At All13
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Thoughts You Be Better Off Dead — Several Days0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 4 Day 1 / PF-06882961 120 mg BID + Atorvastatin 20 mg / Thoughts You Be Better Off Dead — Nearly Every Day0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Not At All13
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Several Days0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — More Than Half The Days0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Nearly Every Day0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Not At All13
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Several Days0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Not At All12
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Several Days0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days1
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Not At All12
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Several Days1
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — More Than Half The Days0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Nearly Every Day0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Not At All8
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Several Days2
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — More Than Half The Days1
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Nearly Every Day2
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Not At All13
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Several Days0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — More Than Half The Days0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Nearly Every Day0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Not At All13
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Several Days0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — More Than Half The Days0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Nearly Every Day0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Not At All13
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Several Days0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Not At All13
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Several Days0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 6 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Not At All11
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Several Days2
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — More Than Half The Days0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Nearly Every Day0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Not At All13
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Several Days0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Not At All11
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Several Days1
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day1
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy — Not At All10
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy — Several Days2
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy — More Than Half The Days1
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy — Nearly Every Day0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Not At All7
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Several Days2
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — More Than Half The Days1
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Nearly Every Day3
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Not At All13
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Several Days0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — More Than Half The Days0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Nearly Every Day0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Not At All13
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Several Days0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — More Than Half The Days0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Nearly Every Day0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Not At All13
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Several Days0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Not At All13
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Several Days0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 6 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Not At All5
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Several Days1
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — More Than Half The Days0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Nearly Every Day0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Not At All6
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Several Days0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Not At All5
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Several Days1
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Not At All5
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Several Days0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — More Than Half The Days1
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Nearly Every Day0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Not At All5
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Several Days0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — More Than Half The Days1
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Nearly Every Day0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Not At All6
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Several Days0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — More Than Half The Days0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Nearly Every Day0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Not At All5
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Several Days1
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — More Than Half The Days0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Nearly Every Day0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Not At All5
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Several Days1
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Not At All6
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Several Days0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 6 Day 19 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Little Interest/Pleasure in Things — Not At All5
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Little Interest/Pleasure in Things — Several Days1
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Little Interest/Pleasure in Things — More Than Half The Days0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Little Interest/Pleasure in Things — Nearly Every Day0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Down Depressed or Hopeless — Not At All5
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Down Depressed or Hopeless — Several Days1
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Falling or Staying Asleep — Not At All5
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Falling or Staying Asleep — Several Days1
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Falling or Staying Asleep — More Than Half The Days0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Falling or Staying Asleep — Nearly Every Day0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Tired or Little Energy — Not At All5
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Tired or Little Energy — Several Days1
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Tired or Little Energy — More Than Half The Days0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Tired or Little Energy — Nearly Every Day0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Poor Appetite or Overeating — Not At All5
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Poor Appetite or Overeating — Several Days0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Poor Appetite or Overeating — More Than Half The Days1
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Poor Appetite or Overeating — Nearly Every Day0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Bad About Yourself — Not At All6
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Bad About Yourself — Several Days0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Bad About Yourself — More Than Half The Days0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Feeling Bad About Yourself — Nearly Every Day0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Concentrating on Things — Not At All5
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Concentrating on Things — Several Days1
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Concentrating on Things — More Than Half The Days0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Trouble Concentrating on Things — Nearly Every Day0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Moving Slowly or Fidgety/Restless — Not At All5
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Moving Slowly or Fidgety/Restless — Several Days1
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Thoughts You Be Better Off Dead — Not At All6
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Thoughts You Be Better Off Dead — Several Days0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 8 Day 1 / PF-06882961 200 mg BID + Midazolam 5 mg / Thoughts You Be Better Off Dead — Nearly Every Day0
Follow Up — Not At All14
Follow Up — Several Days1
Follow Up — More Than Half The Days0
Follow Up — Nearly Every Day0
Secondary(Part B) Number of Participants With Categorical Scores on the PHQ-9

The PHQ-9 is a 9 item self-report scale for the assessment of depressive symptoms. The questions included "little interest/pleasure in things", "feeling down depressed or hopeless", "trouble falling or staying asleep", "feeling tired or little energy", "poor appetite or overeating", "feeling bad about yourself", "trouble concentrating on things", "moving slowly or fidgety/restless" and "thoughts you be better off dead". Each item was scored on scale of "not at all", "several days", "more than half the days" to "nearly every day". Total score range: 0-27 (each item with scale from 0 \[not at all\] to 3 \[nearly every day\]. Higher score=greater severity).

Time frame:
Study Day -1 (D-1) (ie, Period 1 Day-1 [P1D-1]), D6 (P2D1), D13 (P2D8), D20 (P2D15), D27 (P2D22), D37 (P3D1), D42 (P4D1), D50 (P4D9), D60 (P4D19), D66 (P5D6), and at follow-up visit (Days 72-75) of Part B.
Reported as:
Count of participants · Participants
(Part B) Number of Participants With Categorical Scores on the PHQ-9
ParticipantsAll Participants in Part B
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Little Interest/Pleasure in Things — Not At All17
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Little Interest/Pleasure in Things — Several Days0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Little Interest/Pleasure in Things — More Than Half The Days0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Little Interest/Pleasure in Things — Nearly Every Day0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Down Depressed or Hopeless — Not At All16
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Down Depressed or Hopeless — Several Days1
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Falling or Staying Asleep — Not At All17
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Falling or Staying Asleep — Several Days0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Falling or Staying Asleep — More Than Half The Days0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Falling or Staying Asleep — Nearly Every Day0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Tired or Little Energy — Not At All16
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Tired or Little Energy — Several Days1
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Tired or Little Energy — More Than Half The Days0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Tired or Little Energy — Nearly Every Day0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating — Not At All16
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating — Several Days1
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating — More Than Half The Days0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating — Nearly Every Day0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself — Not At All16
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself — Several Days1
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself — More Than Half The Days0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself — Nearly Every Day0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Concentrating on Things — Not At All17
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Concentrating on Things — Several Days0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Concentrating on Things — More Than Half The Days0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Trouble Concentrating on Things — Nearly Every Day0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Moving Slowly or Fidgety/Restless — Not At All17
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Moving Slowly or Fidgety/Restless — Several Days0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Not At All17
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Several Days0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 1 Day -1 / 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Nearly Every Day0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Not At All16
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Several Days0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — More Than Half The Days0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Nearly Every Day0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Not At All16
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Several Days0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Not At All16
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Several Days0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Not At All15
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Several Days1
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — More Than Half The Days0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Nearly Every Day0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Not At All15
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Several Days1
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — More Than Half The Days0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Nearly Every Day0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Not At All15
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Several Days1
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — More Than Half The Days0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Nearly Every Day0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Not At All15
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Several Days1
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — More Than Half The Days0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Nearly Every Day0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Not At All16
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Several Days0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Not At All16
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Several Days0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 2 Day 1 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Not At All16
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Several Days0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — More Than Half The Days0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Nearly Every Day0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Not At All16
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Several Days0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Not At All16
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Several Days0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Not At All15
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Several Days1
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — More Than Half The Days0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Nearly Every Day0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Not At All15
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Several Days1
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — More Than Half The Days0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Nearly Every Day0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Not At All16
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Several Days0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — More Than Half The Days0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Nearly Every Day0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Not At All16
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Several Days0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — More Than Half The Days0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Nearly Every Day0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Not At All16
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Several Days0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Not At All16
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Several Days0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 2 Day 8 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Not At All15
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Several Days1
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — More Than Half The Days0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Nearly Every Day0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Not At All16
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Several Days0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Not At All16
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Several Days0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Not At All15
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Several Days1
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — More Than Half The Days0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Nearly Every Day0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Not At All13
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Several Days1
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — More Than Half The Days2
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Nearly Every Day0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Not At All16
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Several Days0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — More Than Half The Days0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Nearly Every Day0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Not At All16
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Several Days0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — More Than Half The Days0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Nearly Every Day0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Not At All16
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Several Days0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Not At All16
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Several Days0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 2 Day 15 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Not At All15
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Several Days1
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — More Than Half The Days0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Little Interest/Pleasure in Things — Nearly Every Day0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Not At All16
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Several Days0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Not At All16
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Several Days0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Not At All15
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Several Days1
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — More Than Half The Days0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Tired or Little Energy — Nearly Every Day0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Not At All13
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Several Days3
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — More Than Half The Days0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Poor Appetite or Overeating — Nearly Every Day0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Not At All16
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Several Days0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — More Than Half The Days0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Feeling Bad About Yourself — Nearly Every Day0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Not At All16
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Several Days0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — More Than Half The Days0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Trouble Concentrating on Things — Nearly Every Day0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Not At All16
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Several Days0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Not At All16
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Several Days0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 2 Day 22 / PF-06882961 titration up to 120 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day0
Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things — Not At All13
Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things — Several Days1
Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things — More Than Half The Days0
Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things — Nearly Every Day1
Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless — Not At All15
Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless — Several Days0
Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep — Not At All14
Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep — Several Days0
Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep — More Than Half The Days1
Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep — Nearly Every Day0
Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy — Not At All13
Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy — Several Days1
Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy — More Than Half The Days0
Period 3 Day 1 / PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy — Nearly Every Day1
Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating — Not At All10
Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating — Several Days0
Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating — More Than Half The Days3
Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Poor Appetite or Overeating — Nearly Every Day2
Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself — Not At All15
Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself — Several Days0
Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself — More Than Half The Days0
Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Feeling Bad About Yourself — Nearly Every Day0
Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/ Trouble Concentrating on Things — Not At All14
Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/ Trouble Concentrating on Things — Several Days1
Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/ Trouble Concentrating on Things — More Than Half The Days0
Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/ Trouble Concentrating on Things — Nearly Every Day0
Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless — Not At All14
Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless — Several Days0
Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless — More Than Half The Days1
Period 3 Day 1/PF-06882961 120mg BID + 0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Not At All15
Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Several Days0
Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 3 Day 1 / PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Nearly Every Day0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Not At All11
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Several Days1
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — More Than Half The Days0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Nearly Every Day0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Not At All12
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Several Days0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Not At All12
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Several Days0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Not At All10
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Several Days2
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — More Than Half The Days0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Nearly Every Day0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Not At All9
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Several Days0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — More Than Half The Days1
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Nearly Every Day2
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Not At All12
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Several Days0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — More Than Half The Days0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Nearly Every Day0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Not At All12
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Several Days0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — More Than Half The Days0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Nearly Every Day0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Not At All12
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Several Days0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Not At All12
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Several Days0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 4 Day 1 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Not At All11
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Several Days0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — More Than Half The Days0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Little Interest/Pleasure in Things — Nearly Every Day0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Not At All11
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Several Days0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Not At All10
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Several Days1
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — More Than Half The Days0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Falling or Staying Asleep — Nearly Every Day0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Not At All10
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Several Days1
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — More Than Half The Days0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Tired or Little Energy — Nearly Every Day0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Not At All8
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Several Days1
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — More Than Half The Days1
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Poor Appetite or Overeating — Nearly Every Day1
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Not At All11
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Several Days0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — More Than Half The Days0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Feeling Bad About Yourself — Nearly Every Day0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Not At All10
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Several Days1
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — More Than Half The Days0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Trouble Concentrating on Things — Nearly Every Day0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Not At All10
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Several Days1
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Not At All11
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Several Days0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 4 Day 9 / PF-06882961 titration up to 200 mg BID / Thoughts You Be Better Off Dead — Nearly Every Day0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Little Interest/Pleasure in Things — Not At All9
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Little Interest/Pleasure in Things — Several Days0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Little Interest/Pleasure in Things — More Than Half The Days0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Little Interest/Pleasure in Things — Nearly Every Day0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Down Depressed or Hopeless — Not At All9
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Down Depressed or Hopeless — Several Days0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Falling or Staying Asleep — Not At All8
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Falling or Staying Asleep — Several Days1
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Falling or Staying Asleep — More Than Half The Days0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Falling or Staying Asleep — Nearly Every Day0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy — Not At All8
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy — Several Days0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy — More Than Half The Days0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Tired or Little Energy — Nearly Every Day1
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Poor Appetite or Overeating — Not At All7
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Poor Appetite or Overeating — Several Days0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Poor Appetite or Overeating — More Than Half The Days1
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Poor Appetite or Overeating — Nearly Every Day1
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Bad About Yourself — Not At All9
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Bad About Yourself — Several Days0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Bad About Yourself — More Than Half The Days0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Feeling Bad About Yourself — Nearly Every Day0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Concentrating on Things — Not At All8
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Concentrating on Things — Several Days0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Concentrating on Things — More Than Half The Days1
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Trouble Concentrating on Things — Nearly Every Day0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Moving Slowly or Fidgety/Restless — Not At All8
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Moving Slowly or Fidgety/Restless — Several Days0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Moving Slowly or Fidgety/Restless — Nearly Every Day1
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Thoughts You Be Better Off Dead — Not At All9
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Thoughts You Be Better Off Dead — Several Days0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Thoughts You Be Better Off Dead — More Than Half The Days0
Period 4 Day 19 / PF-06882961 titration up to 200 mg BID /Thoughts You Be Better Off Dead — Nearly Every Day0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things — Not At All9
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things — Several Days0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things — More Than Half The Days0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Little Interest/Pleasure in Things — Nearly Every Day0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless — Not At All9
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless — Several Days0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless — More Than Half The Days0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Down Depressed or Hopeless — Nearly Every Day0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep — Not At All8
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep — Several Days0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep — More Than Half The Days0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Falling or Staying Asleep — Nearly Every Day1
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy — Not At All8
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy — Several Days0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy — More Than Half The Days0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Tired or Little Energy — Nearly Every Day1
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Poor Appetite or Overeating — Not At All7
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Poor Appetite or Overeating — Several Days0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Poor Appetite or Overeating — More Than Half The Days1
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Poor Appetite or Overeating — Nearly Every Day1
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Bad About Yourself — Not At All9
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Bad About Yourself — Several Days0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Bad About Yourself — More Than Half The Days0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Feeling Bad About Yourself — Nearly Every Day0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Concentrating on Things — Not At All8
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Concentrating on Things — Several Days0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Concentrating on Things — More Than Half The Days0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Trouble Concentrating on Things — Nearly Every Day1
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless — Not At All8
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless — Several Days0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless — More Than Half The Days0
Period 5 Day 6/PF-06882961 200mg BID+0.15mg LE & 0.03mg EE/Moving Slowly or Fidgety/Restless — Nearly Every Day1
Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Not At All9
Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Several Days0
Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — More Than Half The Days0
Period 5 Day 6 / PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE / Thoughts You Be Better Off Dead — Nearly Every Day0
Follow Up / Little Interest/Pleasure in Things — Not At All11
Follow Up / Little Interest/Pleasure in Things — Several Days0
Follow Up / Little Interest/Pleasure in Things — More Than Half The Days0
Follow Up / Little Interest/Pleasure in Things — Nearly Every Day0
Follow Up / Feeling Down Depressed or Hopeless — Not At All11
Follow Up / Feeling Down Depressed or Hopeless — Several Days0
Follow Up / Feeling Down Depressed or Hopeless — More Than Half The Days0
Follow Up / Feeling Down Depressed or Hopeless — Nearly Every Day0
Follow Up / Trouble Falling or Staying Asleep — Not At All10
Follow Up / Trouble Falling or Staying Asleep — Several Days1
Follow Up / Trouble Falling or Staying Asleep — More Than Half The Days0
Follow Up / Trouble Falling or Staying Asleep — Nearly Every Day0
Follow Up / Feeling Tired or Little Energy — Not At All11
Follow Up / Feeling Tired or Little Energy — Several Days0
Follow Up / Feeling Tired or Little Energy — More Than Half The Days0
Follow Up / Feeling Tired or Little Energy — Nearly Every Day0
Follow Up / Poor Appetite or Overeating — Not At All11
Follow Up / Poor Appetite or Overeating — Several Days0
Follow Up / Poor Appetite or Overeating — More Than Half The Days0
Follow Up / Poor Appetite or Overeating — Nearly Every Day0
Follow Up / Feeling Bad About Yourself — Not At All11
Follow Up / Feeling Bad About Yourself — Several Days0
Follow Up / Feeling Bad About Yourself — More Than Half The Days0
Follow Up / Feeling Bad About Yourself — Nearly Every Day0
Follow Up / Trouble Concentrating on Things — Not At All11
Follow Up / Trouble Concentrating on Things — Several Days0
Follow Up / Trouble Concentrating on Things — More Than Half The Days0
Follow Up / Trouble Concentrating on Things — Nearly Every Day0
Follow Up / Moving Slowly or Fidgety/Restless — Not At All11
Follow Up / Moving Slowly or Fidgety/Restless — Several Days0
Follow Up / Moving Slowly or Fidgety/Restless — More Than Half The Days0
Follow Up / Moving Slowly or Fidgety/Restless — Nearly Every Day0
Follow Up / Thoughts You Be Better Off Dead — Not At All11
Follow Up / Thoughts You Be Better Off Dead — Several Days0
Follow Up / Thoughts You Be Better Off Dead — More Than Half The Days0
Follow Up / Thoughts You Be Better Off Dead — Nearly Every Day0

Adverse events

Collected over From Screening (Days 28 to -2) to follow-up telephone contact (Days 90 to 97) in Part A and from Screening (Days 28 to -2) to follow-up telephone contact (Days 94 to 101) in Part B of the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atorvastatin 20 mg (Part A Period 1)0/18 (0%)0/18 (0%)2/18 (11.1%)
Midazolam 5 mg (Part A Period 2)0/18 (0%)0/18 (0%)3/18 (16.7%)
PF-06882961 Titration up to 120 mg BID (Part A Period 3)0/17 (0%)0/17 (0%)13/17 (76.5%)
PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)0/13 (0%)0/13 (0%)5/13 (38.5%)
PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)0/13 (0%)0/13 (0%)4/13 (30.8%)
PF-06882961 Titration up to 200 mg BID (Part A Period 6)0/13 (0%)0/13 (0%)12/13 (92.3%)
PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)0/5 (0%)0/5 (0%)5/5 (100%)
PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0/6 (0%)0/6 (0%)2/6 (33.3%)
0.15 mg LE & 0.03 mg EE (Part B Period 1)0/17 (0%)0/17 (0%)5/17 (29.4%)
PF-06882961 Titration up to 120 mg BID (Part B Period 2)0/16 (0%)0/16 (0%)15/16 (93.8%)
PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)0/14 (0%)0/14 (0%)7/14 (50%)
PF-06882961 Titration up to 200 mg BID (Part B Period 4)0/12 (0%)0/12 (0%)12/12 (100%)
PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)0/9 (0%)0/9 (0%)7/9 (77.8%)
Most frequent other events
Showing 10 of 55
Most frequent other events
EventAtorvastatin 20 mg (Part A Period 1)Midazolam 5 mg (Part A Period 2)PF-06882961 Titration up to 120 mg BID (Part A Period 3)PF-06882961 120 mg BID + Atorvastatin 20 mg (Part A Period 4)PF-06882961 120 mg BID + Midazolam 5 mg (Part A Period 5)PF-06882961 Titration up to 200 mg BID (Part A Period 6)PF-06882961 200 mg BID + Atorvastatin 20 mg (Part A Period 7)PF-06882961 200 mg BID + Midazolam 5 mg (Part A Period 8)0.15 mg LE & 0.03 mg EE (Part B Period 1)PF-06882961 Titration up to 120 mg BID (Part B Period 2)PF-06882961 120 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 3)PF-06882961 Titration up to 200 mg BID (Part B Period 4)PF-06882961 200 mg BID + 0.15 mg LE & 0.03 mg EE (Part B Period 5)
NauseaGastrointestinal disorders0/180/1810/172/131/133/130/50/60/1712/160/141/122/9
SARS-CoV-2 test positiveInvestigations0/180/182/170/130/138/133/50/60/170/160/140/120/9
HeadacheNervous system disorders1/181/183/170/130/133/131/51/61/177/163/146/123/9
Abdominal discomfortGastrointestinal disorders0/180/185/170/131/132/130/50/60/177/161/144/123/9
VomitingGastrointestinal disorders0/180/182/171/131/135/131/50/60/175/161/143/122/9
ConstipationGastrointestinal disorders0/180/186/173/130/134/130/50/60/170/160/142/120/9
Decreased appetiteMetabolism and nutrition disorders0/180/183/171/130/132/130/50/60/174/161/140/120/9
DizzinessNervous system disorders0/180/182/170/130/131/130/51/61/173/161/143/120/9
DiarrhoeaGastrointestinal disorders0/180/180/170/130/130/130/50/60/173/160/143/122/9
FatigueGeneral disorders0/180/180/170/131/130/131/50/60/171/160/141/120/9

Baseline characteristics

All enrolled participants who received at least 1 dose of study intervention

Age, Continuous
Age, Continuous(Years)All Participants in Part AAll Participants in Part BTotal
Mean (SD)41.2 ± 11.6354.5 ± 4.1647.7 ± 11.01
Age, Customized
Age, Customized(Participants)All Participants in Part AAll Participants in Part BTotal
<18 Years000
18-25 Years202
26-35 Years404
36-45 Years404
>45 Years81725
Sex: Female, Male
Sex: Female, Male(Participants)All Participants in Part AAll Participants in Part BTotal
Female21719
Male16016
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants in Part AAll Participants in Part BTotal
White151429
Black or African American224
Asian112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants in Part AAll Participants in Part BTotal
Hispanic or Latino8917
Not Hispanic or Latino10818
08

Study locations

1 site
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Jul 2022, 8 months.

Results were first posted in Aug 2024, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2021
First posted
Oct 26, 2021
StartActual
Oct 25, 2021
Primary completionActual
Jul 6, 2022
CompletionActual
Jul 6, 2022
Results first posted
Aug 19, 2024
Last update
Aug 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05093205
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 26, 2021
Start date
Oct 25, 2021
Primary completion
Jul 6, 2022
Completion
Jul 6, 2022
Results posted
Aug 19, 2024
Last update
Aug 19, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Danuglipron · Atorvastatin

Start the discussion